Press Release March 05, 2015

Goodwin Advises AMAG Pharmaceuticals on $201 Million Common Stock Offering

Goodwin Procter attorneys recently advised AMAG Pharmaceuticals in connection with the company’s public offering of more than 4.5 million shares of common stock at a price of $44.00 per share.  The offering, in which underwriters fully exercised their option to purchase an additional 596,590 share, had gross proceeds of approximately $201.2 million. J.P. Morgan and Deutsche Bank Securities acted as joint book-running managers for the offering. Cowen and Company and Baird acted as co-managers.

AMAG Pharmaceuticals, traded on Nasdaq under ticker “AMAG,"  is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG is to bring to market therapies that provide clear benefits and improve patients' lives. In addition to continuing to pursue opportunities to make new advancements in patients' health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies. The company is based in Waltham, Mass.

The Goodwin team advising AMAG was led by partners Stuart Cable, Ettore Santucci and Jim Matarese, and included associates Jacqueline Mercier, William Collins, Erini Svokos and Robert Dzialo (corporate), partner Janet Andolina and associate Alex Plaum (tax), and partner Theresa Kavanaugh.

Additional information is available in the AMAG press release announcing the close of the offering.